R&D channel feed – Endpoints News

R&D channel feed

#ASH22 roundup: CSL shows two years of data in $3.5M hemophilia gene therapy; Syndax shows 30% CR rate from March data cut

3 years ago

#ASH22: Regeneron reveals its first PhII data in contested CD20xC3 bispecific race

3 years ago

#ASH22: Bristol Myers reports next-gen CAR-T data as rival’s bispecific heads to FDA, and gives alnuctamab another shot

3 years ago

#ASH22: Lilly’s Loxo spells out BTK data as it eyes BeiGene, AbbVie/J&J and AstraZeneca

3 years ago

#ASH22: 'Not so surprising': With lack of durability, Affimed scraps monotherapy plans in favor of NK cell combo

3 years ago

#ASH22: J&J touts first PhII results of next-gen multiple myeloma antibody

3 years ago

#ASH22: Kura’s menin inhibitor heads to PhII in subset of acute myeloid leukemia with mixed data

3 years ago

#ASH22: Adicet touts longer-term CR data after ASCO win

3 years ago

Updated: Gilead, Arcellx team up on anti-BCMA CAR-T as biotech touts a 100% response rate at #ASH22

3 years ago

Replimune looks to rope in $225M on the back of melanoma data

3 years ago

Exelixis drug fails PhIII lung cancer trial with Cabometyx and Tecentriq combo

3 years ago

Autolus tips its hand, bags $220M as CAR-T showdown with Gilead looms

3 years ago

Ready for takeoff: ARPA-H intros plan to attract project investors, commercialize products

3 years ago

CNS biotech's stock dives — again — as lead candidate fails second PhIII test

3 years ago

Nearly out of cash, a former Sarepta partner asks French courts to oversee restructuring

3 years ago

Scoop: Gilead terminates early-stage FLT3 trial in solid tumors

3 years ago

AstraZeneca’s Susan Galbraith highlights twin wins for the cancer drug pipeline at SABCS, as oral SERD excels

3 years ago

Novartis' iptacopan meets PhIII test in fight against rare blood disease

3 years ago

Amgen vet's new biotech nets $47M Series A for polymer-based ADCs

3 years ago

With clear PhII win in IBD, Prometheus thwarts Pfizer comparisons as it follows Humira 'playbook'

3 years ago

Avrobio touts early clinical data and plans new gene therapy trial in 2023

3 years ago

Just days before presenting at ASH conference, Syndax outlines plan to raise $150M

3 years ago

Penny stock pulls back on offering up more of its shares amid ‘current market conditions’

3 years ago

Neurocrine's $50M bet on Idorsia drug flames out in second PhII

3 years ago

First page Previous page 107 108 109110111 112 113 Next page Last page